Colgate-Palmolive (CL) announced that Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company (BMY), has been elected to Colgate-Palmolive’s Board of Directors effective March 15, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Oil Prices Fall as Trump Says Iran War Could End Soon But Escalates Threats
- Execution Risks Loom Over Colgate-Palmolive’s 3-Year Strategic Growth and Productivity Program
- Colgate-Palmolive price target raised to $105 from $100 at BofA
- Colgate-Palmolive: Reaccelerating Growth from Pet Nutrition, Emerging Markets, and Innovation Makes CL a Preferred Buy
- Colgate-Palmolive price target raised to $100 from $94 at Goldman Sachs